-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Stoke Therapeutics, Maintains $39 Price Target

Benzinga·05/11/2026 09:52:55
Listen to the news
BTIG analyst Thomas Shrader reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $39 price target.